1. Introduction
Trimethoprim (TMP)1 (2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine is an antibiotic used to treat and prevent urinary tract infections and treat ear infections caused by certain bacteria.2 It is also used in combination with sulfamethoxazole to treat several infections, including those of the gastrointestinal tract, respiratory tract, and urinary tract. The chemical formula of TMP is C14H18N4O3 molar mass 290.32 g mol−1.3,4 (Fig. 1) shows the structural formula of TMP.
Fig. 1. Structural formula of TMP.
The determination of TMP in pharmaceutical preparations including spectrophotometric methods,5,6 spectrofluorometric methods,7 liquid chromatography,8 HPLC,9,10 Micellar electrokinetic capillary chromatography,11 voltammetry,12 Continuous wavelet transforms,13 Electrochemical14 and ion-selective electrode (ISE).15 This study used the spectrofluorometric method for the determination of trimethoprim according to the reaction with O-phthalaldehyde and 2-mercaptoethanol in alkaline media to form a labeling fluorescent product at λexc = 342 nm and λem.= 458 nm. In comparison to several other methods, which require costly hazardous solvents and sample pretreatment, this method is characterized by simplicity, rapidity, and reproducibility, allowing them to be used in routine analysis of trimethoprim in pharmaceutical formulations.
The limitations of this study are the inability to estimate trimethoprim in the presence of other primary amino compounds since those compounds may produce fluorescent chemical compounds that interfere with the fluorescence spectrum of OPA-2ME-TMP fluorophore. In this case, a method must be followed to resolve this overlap in order to the determination of trimethoprim, such as the H-point standard addition method, derivative spectrophotometric method, etc. Also, this reaction cannot be carried out in acidic or neutral media because OPA reacts with 2ME and TMP to form a stable isoindole ring only in alkaline media (pH 8-12).
2. Experimental
2.1. Apparatus
Fluorescence spectra were collected by using a Shimadzu (RF-5301 PC, Kyoto, Japan) equipped with a 150 W xenon lamp and a photomultiplier tube. Slit width set at 5 nm for both excitation and emission monochromatic. All pH measurements were made with a digital pH meter (in-lab pH 720, Germany). Sensitive digital balance (BP 3015, Sartorius Germany).
2.2. Chemicals and reagents
A stock solution of Trimethoprim (TMP) (100 μg·mL−1) was prepared by dissolving 10 mg of TMP in 100 mL of distilled water. The working standard solutions were prepared by suitable dilution with distilled water to the appropriate concentration. O-phthalaldehyde (OPA) (0.1 w/v%) was prepared by dissolving (100) mg of (OPA) in 100 mL of methanol. 2-mercaptoethanol (2ME) (1 v/v%) was prepared by pipetting 1 mL of 2-mercaptoethanol into 100 mL volumetric flask and completing the volume with methanol. Boric acid (0.2 mol·L−1) was prepared by accurately weighed of 1.237 g, and dissolved in 100 mL of distilled water. Borate buffer solution was prepared from 0.2 mol·L−1 boric acid and 1.00 mol·L−1 sodium hydroxide. The sodium hydroxide solution was added drop by drop to the boric acid solution, with stirring, until a pH of (9.4) was reached.
2.3. Recommended procedure
Aliquots of TMP working standard solutions were quantitatively transferred using a micropipette into sets of 10 mL volumetric flasks to prepare a TMP concentration within the range of (100-1200 ng mL−1). Then, 2 mL of 0.2 molq·L−1 borate buffer solution at (pH = 9.8) together with 1 mL of 1 %v/v 2-ME were added for each flask and mixed well. The reaction mixture was allowed to stand for 4 min. Thereafter, 2.5 mL of 0.1 % w/v OPA was added and mixed gently. The reaction mixture was left again for 40 min at room temperature. The solution in each flask was made up to the mark by methanol solvent. The intensity of the resulting solution is measured at λem 458 nm when excited at λexc 342 nm.
3. Results and Discussion
The O-Phthalaldehyde (OPA) is a most popular fluorogenic agent that is widely used for the detection of a nanogram of compounds with primary amine moiety. Primary amines such as TMP form a highly fluorescent compound when they react with OPA and a thiol compound (like 2-mercaptoethanol) through condensation reaction under basic condition. The reaction is essentially complete within 5.0-40.0 minutes. The reaction product intensity is attributed to the formation of the isoindole group which triggers the compound to give fluorescence intensity as shown in (Fig. 2). The fluorescence spectrum of OPA-2ME-TMP fluorophores using drugs concentration 300 ng mL−1 was shown in (Fig. 3). The formed fluorophores exhibit an excitation wavelength of 342nm with emission wavelengths of 458 nm.
Fig. 2. The suggested reaction between TMP and OPA reagent.
Fig. 3. Fluorescence spectrum of OPA-2ME-TMP fluorophores.
3.1. Optimization of conditions
The experimental parameters of the proposed method that effect on fluorescence intensity of OPA-2ME-TMP fluorophore were estimated and optimized.
3.1.1. Effect of pH and buffer's volume
To investigate the impact of PH value on the formation of the fluorescent compound, a series of buffer solutions were used in the pH range (6.5-11.5). The fluorescent intensity of the formed OPA-2ME-TMP fluorophore increases as a function of solution pH until it reaches a maximum value at pH=10.0 and no longer increases. Otherwise, it decreased gradually due to may be of background compound formation. The influence of borate buffer volume in the range of (0.5-4.0 mL) on the fluorescent intensity of the formed fluorophore was studied at (pH = 9.8), the maximum fluorescent intensity was reached at 2 mL which was selected as the optimal buffer volume. As observed in (Fig. 4(a)).
Fig. 4. Effect of various experimental parameters on the fluorescence intensity of the OPA-2ME-TMP fluorophore.
3.1.2. Effect of OPA volume
The effect of different volumes of OPA reagent on the formation of the fluorescent complex has been studied. Fig. 4(b) shows that (2.5) mL of 0.1 % w/v OPA was optimized and selected for subsequent experiments.
3.1.3. Effect of 2-mercaptoethanol volume
Different volumes of 2-ME 0.5 % w/v within the range (0.1-2.0 mL) were used. Hence, 1 mL of 2-mercaptoethanol was selected as the optimal volume as shown in (Fig. 4(c)).
3.1.4. Effect of time after addition of 2-mercaptoethanol
The effect of time after the addition 2-mercaptoethanol on the fluorescence intensity of the fluorescent compound was tested. As shown in (Fig. 4(c)). Five minutes was selected as the optimal time to formation of thiolate ion.
3.1.5. Effect of reaction time
The time required for the reaction completion was investigated. The results indicated that (40) min is sufficient to complete the reaction as observed in (Fig. 4(c)).
3.1.6. Solvents effect
To select a more suitable solvent that obtains the highest fluorescence intensity of the formed fluorophore different solvents were tested, such as acetone, acetonitrile, methanol, butanol, ethyl acetate, DMSO, ethanol, DMF and distilled water. It was found that the dilution of the reaction mixture with methanol gives maximum fluorescent intensity.
3.2. Method validation
3.2.1. Calibration curve
The values of the fluorescence intensity at 458 nm were plotted vs TMP concentration to obtain a calibration curve whose linear In concentration range (100-1200) ng·mL−1 as shown in (Fig. 5). The regression parameters were illustrated in Table 1.
Fig. 5. Calibration curve of TMP drug.
Table 1. Analytical parameters of the suggested approach
LODa : Limit of detection. LOQb : Limit of quantitation
3.2.2. Accuracy
The suggested approach accuracy was verified by measuring the fluorescence intensity of TMP-2ME-OPA by selecting three concentration levels within the calibration curve (500, 800, and 1000) ng·mL−1) by repeating the experiment five times for each concentration. As shown in (Table 2). The percent recovery (Re%) was obtained by analyzing the results. The Re% values indicate that the proposed method is highly accurate.
Table 2. Accuracy data of the suggested spectrofluorimetric method
*Mean of five determinations
3.2.3. Precision
Three concentrations of TMP (300, 600 and 900 ng·mL−1) were prepared and analyzed to verify the precision of the suggested method. The R.S.D% of the results was less than 2 indicating acceptable precision as shown in Table 3.
Table 3. Precision of the proposed method
*Mean of five determinations
3.2.4. Robustness
To verify the robustness of the proposed method, three experimental variables (OPA volume, pH, and 2-ME volume) were slightly altered in this study. The slight alterations in conditions of the experiment did not effect on the determination of TMP by suggested method. As shown in Table 4.
Table 4. Robustness evaluation for the proposed approach
*Mean of five determinations.
3.3. Application
Trimethoprim has been successfully estimated by the proposed method in its pharmaceutical tablets as shown in Table 5. The results of the suggested method have been statistically compared with those obtained by the official methods. Table 6 shows that the ttest and Ftest values of the proposed method were less than theoretical ones, which indicates that the suggested approach can be effectively used to determination of TMP in a real pharmaceutical preparation (Tablets). The results reported by many published methods for the determination of TMP are given in Table 7. As can be seen, the lowest detection limit was obtained for the determination of TMP by the proposed method.
Table 5. Determination of TMP in different pharmaceutical preparations
*Mean of five determinations
Table 6. Statistical comparison between the proposed and official method
Table 7. The most important methods used for the determination of TMP
4. Conclusions
The spectrofluorimetric method has been proposed for the estimation of TMP in pure and pharmaceutical dosage forms according to the reaction of TMP with OPA in highly alkaline media in the presence of 2-mercaptoethanol and this reaction gives fluorescent product measured at (458) nm when excited at (342) nm within a concentration range (100-1200) ng.mL–1 and low detection limit (22.54) ng·mL–1.
The proposed method can determine the unknown concentration of analyte giving a heightened precision and accuracy, where the value of R.S.D% is less than 2 % and the recovery percentage is equal to 100.5 % and 99.76 % for the determination of TMP in pure and real pharmaceutical formulations respectively.
Acknowledgements
This study is a part of the PhD thesis of Amneen Mohammed Abdulkaream.
참고문헌
- J. H. Darrell, L. P. Garrod, and P. M. Waterworth, J. Clin. Pathol., 21, 202-209 (1968). http://dx.doi.org/10.1136/jcp.21.2.202
- S. G. B. Amyes and J. T. Smith., Biochem. Biophy. Res. Commun., 58(2), 412-418 (1978). https://doi.org/10.1016/0006-291X(74)90380-5
- M. A. Perazella, Drug Safety, 22, 227-236 (2000). https://doi.org/10.2165/00002018-200022030-00006
- R. Gleckman, M. S. Alvarez, and D. W. Joubert, Am. J. Hosp. Pharm., 36(7), 893-906 (1979). https://doi.org/10.1093/ajhp/36.7.893
- S. Z. Qureshi, M. I. H. Helaleh, N. Rahman, and R. M. A. Q. Jamhour, Fresenius J. Anal. Chem., 357, 1005-1007 (1997). https://doi.org/10.1007/s002160050293
- S. E. Hismiogullari and E. Yarsan, Hacettepe University Journal of the Faculty of Pharmacy, Year 2009(2), 95-104 (2009).
- D. M. Lichtenwalner, B. Suh, B. Lorber, and A. M. Sugar, Antimicrob. Agents Chemother., 16(5), 579-83 (1979). https://doi.org/10.1128/aac.16.5.579
- C. Akay and S. A. Ozkan, J. Pharm. Biomed. Anal., 30(4), 1207-1213 (2002). https://doi.org/10.1016/s0731-7085(02)00460-0
- E. Sayar, S. Sahin, S. Cevheroglu, and A. A. Hincal, Eur. J. Drug Metab. Pharmacokinet, 35, 41-46 (2010). https://doi.org/10.1007/s13318-010-0006-9
- R. W. Bury and M. L. Mashford, J. Chromatogr., 163, 114-117 (1979). https://doi.org/10.1016/S0378-4347(00)81178-0
- J. J. Berzas, G. C. Penalvo, and F. J. Guzman Bernardo, J. Sep. Sci., 28(6), 543-548 (2005). https://doi.org/10.1002/jssc.200400098
- G. N. Calaca, C. A. Pessoa, K. Wohnrath, and N. Nagata, Int. J. Pharm. Pharm. Sci., 6(9), 438-442 (2014).
- E. Dinc, Y. Kadioglu, F. Demirkaya, and D. Baleanu, J. Iran. Chem. Soc., 8, 90-99 (2011). https://doi.org/10.1007/BF03246205
- L. G. Chatten, B. S. Pons, and P. Mcleod, Analyst, 107, 1026-1031 (1982). https://doi.org/10.1039/an9820701026
- M Aboudan, Y M. Issa, and A F. Shoukry, J. Chem. Tech. Biotechnol., 61(1), 31-35 (1994). https://doi.org/10.1002/JCTB.280610105
- The British Pharmacopoeia, Stationary Office, Appendix 1D, Buckingham Palace Road, London, UK, 2016.
- T. Al-Sabha and I. A. Hamody, Journal of Education and Science, 24(2), 1-11 (1999). https://doi.org/10.33899/edusj.1999.58728
- M. R. Raauf, Tikrit J. Pharm. Sci., 8(2), 217-228 (2023). https://doi.org/10.25130/tjphs.2012.8.2.10.217.228
- P. Nagaraja,; A. Shrestha, A. Shivakumar, and A. K. Gowda, J. Food Drug Anal., 18(4), 239-248 (2010). https://doi.org/10.38212/2224-6614.2244
- O. Spreux-Varoquaux, J. P. Chapalain, P. Cordonnier, C. Advenier , M. Pays, and L. Lamine, J. Chromatogr. B Biomed. Sci. Appl., 274, 187-199 (1983) https://doi.org/10.1016/s0378-4347(00)84422-9
- K. Hoppu and P. Arjomaa, Clin. Chim. Acta, 163(1), 81-86 (1987). https://doi.org/10.1016/0009-8981(87)90036-2
- M. J. B. Mengelers, M. B. M. Oorsprong, H. A. Kuiper, M. M. Aerts, E. R. van Gogh, and A. S. J. P. A. M. van Miert, J. Pharm. Biomed. Anal., 7(12), 1765-1776 (1989). https://doi.org/10.1016/0731-7085(89)80192-X
- G. C. Batzias, N. A. Botsoglou, V. P. Kotsaki-Kovatsi, and G. Kounenis, J. Chromatogr. B, 769, 253-259 (2002). https://doi.org/10.1016/S1570-0232(01)00625-0
- M. W. Hruska and R. F. Frye, J. Chromatogr. B, 807(2), 301-305 (2004). https://doi.org/10.1016/j.jchromb.2004.04.021
- T. T. Guaraldo, L. A. Goulart, F. C. Moraes, and M. R. V. Lanza, Appl. Surf. Sci., 470, 555-564 (2019). https://doi.org/10.1016/j.apsusc.2018.09.226
- S. A. Abrahem, A. M. Abass, and A. Ahmed, Asian J Pharm. Clin. Res., 12(6), 83-87 (2019). https://doi.org/10.22159/ajpcr.2019.v12i6.32959
- A. Mahmoud, M. I. Yousry, and F. S. Adel, J. Chem. Tech. Biotechnol., 61, 31-35 (1994), https://doi.org/10.1002/jctb.280610105
- A. Bagheri and S. R. Khomami, J. Appl. Chem. Res., 7(3), 25-33 (2013). https://dorl.net/dor/20.1001.1.20083815.2013.7.3.3.0 1001.1.20083815.2013.7.3.3.0
- M. L. Fernandez, P. O. Barrales, G. R. Torne and A. M. Diꠛaz, J. Pharm. Biomed. Anal., 31(4), 669-677 (2003). https://doi.org/10.1016/S0731-7085(02)00685-4
- A. Waseem, M. Yaqoob, and A. Nabi, J. Chem. Soc. Pakistan, 30, 703-707 (2008). https://doi.org/10.4172/pharmaceutical-sciences.1000243
- W. Z. Liu and J. Q. Gao, Acta Pharmacol. Sin., 26(9), 710-713 (1991)